PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30249750-6	2018	The possibility of MI-2 treatment in DSS-induced colitis, associated with restoration of healthy microbially diverse populations in addition to reshaping host immune modulating capacity by reducing inflammatory cytokines (tumor necrosis factor alpha, interleukin-1beta [IL-1beta], IL-17alpha, and IL-22), may be considered therapeutic for ulcerative colitis.	MI-2	19-23	interleukin 17A	Mus musculus	281-291